{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensitive+Skin&page=34", "query": { "condition": "Sensitive Skin", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 1054, "total_pages": 106, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensitive+Skin&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sensitive+Skin&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T17:16:00.332Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06810050", "title": "Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis (AD)" ], "interventions": [ { "name": "CGB-500 with 0.5% tofacitinib", "type": "DRUG" }, { "name": "CGB-500 Ointment with 1% tofacitinib", "type": "DRUG" }, { "name": "Vehicle (placebo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CAGE Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 180, "start_date": "2024-12-18", "completion_date": "2025-10-30", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-11-13T17:16:00.332Z", "location_count": 16, "location_summary": "Fremont, California • Manhattan Beach, California • San Diego, California + 13 more", "locations": [ { "city": "Fremont", "state": "California" }, { "city": "Manhattan Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Doral", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06810050" }, { "nct_id": "NCT01219023", "title": "Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hand Foot Syndrome", "Palmar Plantar Erythrodysesthesia" ], "interventions": [ { "name": "sildenafil citrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 10, "start_date": "2010-06", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-10-30", "last_synced_at": "2026-11-13T17:16:00.332Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01219023" }, { "nct_id": "NCT03687359", "title": "Observational Evaluation of Atopic Dermatitis in Pediatric Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Dermatitis Atopic" ], "interventions": [ { "name": "Standard of care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "0 Years to 11 Years" }, "enrollment_count": 1860, "start_date": "2019-08-15", "completion_date": "2035-07-23", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-11-13T17:16:00.332Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03687359" }, { "nct_id": "NCT01337635", "title": "Vitamin D Deficiency and Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Atopic Dermatitis", "Vitamin D Deficiency" ], "interventions": [ { "name": "Vitamin D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 7, "start_date": "2010-11", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2018-12-05", "last_synced_at": "2026-11-13T17:16:00.332Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01337635" }, { "nct_id": "NCT01544348", "title": "A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Allergic Asthma", "Atopic Dermatitis", "Allergic Rhinitis", "Healthy Volunteers" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Omalizumab", "type": "BIOLOGICAL" }, { "name": "MEDI4212 5 mg Subcutaneous", "type": "BIOLOGICAL" }, { "name": "MEDI4212 15 mg Subcutaneous", "type": "BIOLOGICAL" }, { "name": "MEDI4212 60 mg Subcutaneous", "type": "BIOLOGICAL" }, { "name": "MEDI4212 150 mg Subcutaneous", "type": "BIOLOGICAL" }, { "name": "MEDI4212 300 mg Subcutaneous", "type": "BIOLOGICAL" }, { "name": "MEDI4212 300 mg Intravenous", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 295, "start_date": "2012-01", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-12-30", "last_synced_at": "2026-11-13T17:16:00.332Z", "location_count": 7, "location_summary": "Cypress, California • Glendale, California • Denver, Colorado + 4 more", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01544348" }, { "nct_id": "NCT07931170", "title": "Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "IgA Nephropathy (IgAN)", "IgA Vasculitis", "Idiopathic Immune Complex Glomerulonephritis", "C3 Glomerulopathy", "Membranous Nephropathy", "Focal and Segmental Glomerulosclerosis", "Minimal Change Disease", "Anti-Neutrophilic Cytoplasmic Antibody-GN (ANCA)", "Lupus Nephritis (LN)", "Alport Syndrome", "Infection-related or Post-infectious Glomerulonephritis", "Idiopathic Nephrotic Syndrome (INS)" ], "interventions": [], "intervention_types": [], "sponsor": "Pediatric Nephrology Research Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 1000, "start_date": "2026-10-01", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-13T17:16:00.332Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Cincinnati, Ohio", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07931170" }, { "nct_id": "NCT04271514", "title": "A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "RPT193", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RAPT Therapeutics, Inc., a member of the GSK plc group of companies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 103, "start_date": "2019-08-12", "completion_date": "2021-04-26", "has_results": false, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-11-13T17:16:00.332Z", "location_count": 13, "location_summary": "Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04271514" }, { "nct_id": "NCT00346398", "title": "Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma", "Allergic Sensitization" ], "interventions": [ { "name": "Oral mucosal immunoprophylaxis (OMIP)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Months", "sex": "ALL", "summary": "12 Months to 30 Months" }, "enrollment_count": 51, "start_date": "2006-05", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2017-05-01", "last_synced_at": "2026-11-13T17:16:00.332Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00346398" }, { "nct_id": "NCT06238765", "title": "CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atopic Dermatitis" ], "interventions": [], "intervention_types": [], "sponsor": "CorEvitas", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "15 Years", "sex": "ALL", "summary": "10 Years to 15 Years" }, "enrollment_count": 1500, "start_date": "2023-12-02", "completion_date": "2099-12-31", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-11-13T17:16:00.332Z", "location_count": 1, "location_summary": "Waltham, Massachusetts", "locations": [ { "city": "Waltham", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06238765" }, { "nct_id": "NCT03472040", "title": "A Long Term Safety Study of BCX7353 in Hereditary Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hereditary Angioedema", "HAE", "Prophylaxis" ], "interventions": [ { "name": "BCX7353", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 387, "start_date": "2018-02-16", "completion_date": "2022-04-27", "has_results": true, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-11-13T17:16:00.332Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bentonville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03472040" } ] }